Any references to past performance, regarding financial markets or otherwise, do not indicate or guarantee future results. Nothing contained on our Site constitutes a solicitation, recommendation, endorsement, or offer by MoneyMade or any third party service provider to buy or sell any securities or other financial instruments in this or in in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction.
The Content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. While MoneyMade generally considers such sources to be reliable, MoneyMade does not represent that such information is accurate or complete, and MoneyMade has not undertaken any independent review of such information. The information contained herein regarding available investments is obtained from third party sources. The investments identified on the MoneyMade website may not be purchased through MoneyMade rather, all transactions will be directly between you and the third-party platform hosting the applicable investment. I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.MoneyMade is not a registered broker-dealer or investment adviser.
#Stockpile reviews registration#
I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. This study was funded by grants from the Army Research Office (W911NF1910384) and National Institutes of Health (1R01AI46592-01) Author Declarations The authors have declared no competing interest. Altogether, these findings provide a rationale for nations with extensive vaccine stockpiles to share with other nations. Moreover, we find that there are hybrid sharing policies that have a negligible effect on fatalities in the donor nation compared to the optimal policy while significantly reducing fatalities in the recipient nation. Despite acting selfishly, vaccine sharing by a donor nation significantly reduces transmission and fatalities in the recipient nation. This effect is intensified as vaccination rates decrease and epidemic coupling increases. Mechanistically, sharing a vaccine stockpile reduces the intensity of outbreaks in the recipient nation, in turn reducing travel-associated incidence in the donor nation. Despite the selfish objective, we find it is often optimal for a donor nation to share a significant fraction of its vaccine stockpile. Here we use a two-nation coupled epidemic model to evaluate optimal vaccine-sharing policies given a selfish objective: in which countries with vaccine stockpiles aim to minimize fatalities in their own populations.
For example, as of April 2022 only ∼20% of the population in Africa has received at least one COVID-19 vaccine dose. However, vaccine protectionism by wealthy nations has limited progress towards vaccine sharing goals. The COVAX program aims to provide global equitable access to life-saving vaccines.
0 kommentar(er)
